Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05955183 · ClinicalTrials.gov registry record · Phase 1

Study to Assess the Safety, Tolerability and Pharmacokinetics of AZD5055 in Japanese and Chinese Healthy Volunteers..

A Phase 1 study of Healthy Participants, sponsored by AstraZeneca.

Completed
Registry status
Phase 1
Development phase
38
Enrollment target
1
Study location

NCT05955183 is a Phase 1 study of Healthy Participants that has completed, run by AstraZeneca. The registered enrollment target is 38 participants, below the 65-participant average among 119 other Healthy Participants trials with a reported enrollment target (42% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05955183, a Phase 1 study of Healthy Participants, has completed, sponsored by AstraZeneca.

COMPLETED
Registry status
Phase 1
Development phase
38 participants
Enrollment target
1
Study location

Study Summary

This study will evaluate the pharmacokinetics (PK), pharmacodynamics (PD), safety, and tolerability of AZD5055 after single and multiple doses, orally administered in healthy Japanese and Chinese participants.

Conditions Studied

Interventions

  • DRUG Placebo
  • DRUG AZD5055

Study Locations (1)

California

  • Research Site - Glendale

Trial Details

FieldValue
Enrollment Target 38 participants
Start Date 2023-07-27
Est. Completion 2023-12-04
Phase Phase 1

Sponsor

AstraZeneca

1,285 total trials

What the Registry Record Tells You About NCT05955183

The ClinicalTrials.gov registry entry for NCT05955183 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 38 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 65-participant average among 119 other Healthy Participants trials with a reported enrollment target (42% lower). The listed sponsor is AstraZeneca, which has 1,285 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Healthy Participants appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.

NCT05955183 reports 1 study location spanning 1 distinct geographic area - top geographies include California.

Frequently Asked Questions

What is clinical trial NCT05955183 about?

NCT05955183 is a clinical study titled "Study to Assess the Safety, Tolerability and Pharmacokinetics of AZD5055 in Japanese and Chinese Healthy Volunteers..". This study will evaluate the pharmacokinetics (PK), pharmacodynamics (PD), safety, and tolerability of AZD5055 after single and multiple doses, orally administered in healthy Japanese and Chinese participants.

What is the current status of trial NCT05955183?

This trial is currently completed. It is a Phase 1 study. The enrollment target is 38 participants. The study started on 2023-07-27. Estimated completion is 2023-12-04.

What conditions does trial NCT05955183 study?

This clinical trial studies the following conditions: Healthy Participants.

What interventions are being tested in trial NCT05955183?

The interventions under investigation include: Placebo (DRUG), AZD5055 (DRUG).

Who is sponsoring clinical trial NCT05955183?

This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT05955183 being conducted?

This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Healthy Participants

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.